Nonpsychoactive phytocannabinoids (pCBs) from Cannabis sativa may represent novel therapeutic options for cachexia because of their pleiotropic pharmacological activities, including appetite stimulation. We have recently shown that purified cannabigerol (CBG) is a novel appetite stimulant in rats. As standardized extracts from Cannabis chemotypes dominant in one pCB [botanical drug substances (BDSs)] often show greater efficacy and/or potency than purified pCBs, we investigated the effects of a CBG-rich BDS, devoid of psychoactive Δ 9 -tetrahydrocannabinol, on feeding behaviour. Following a 2 h prefeed satiation procedure, 16 male Lister-hooded rats were administered CBG-BDS (at 30-240 mg/kg) or vehicle. Food intake, meal pattern microstructure and locomotor activity were recorded over 2 h. The total food intake was increased by 120 and 240 mg/kg CBG-BDS (1.53 and 1.36 g, respectively, vs. 0.56 g in vehicletreated animals). Latency to feeding onset was dose dependently decreased at all doses, and 120 and 240 mg/kg doses increased both the number of meals consumed and the cumulative size of the first two meals. No significant effect was observed on ambulatory activity or rearing behaviour. CBG-BDS is a novel appetite stimulant, which may have greater potency than purified CBG, despite the absence of Δ 9 -tetrahydrocannabinol in the extract. Behavioural Pharmacology 28:280-284
Introduction
There is an urgent unmet clinical need for well-tolerated pharmacotherapeutics for cancer-induced and chemotherapyinduced cachexia. Phytocannabinoids (pCBs) from Cannabis sativa may represent viable candidates for this indication because of their pleiotropic pharmacological activities, including modulation of feeding behaviour, metabolic homeostasis and inflammation (Brodie et al., 2015) .
Although the appetite-stimulating properties of C. sativa have historically been attributed to the psychoactive pCB Δ 9 -tetrahydrocannabinol (Δ 9 -THC), we have previously shown that C. sativa extracts containing little or no Δ 9 -THC still stimulate appetite in rats (Farrimond et al., 2011) , and that purified pCBs other than Δ 9 -THC can modulate feeding behaviours (Farrimond et al., 2012) . Recent studies have investigated isolated nonpsychoactive pCBs (with known anti-inflammatory and/ or anti-tumour activities) for their ability to stimulate feeding, and thus their potential as novel cachexia treatments. One such pCB is cannabigerol (CBG), which attenuates inflammatory bowel disease and colon carcinogenesis in vivo (Borrelli et al., 2013 (Borrelli et al., , 2014 and has in-vitro affinities for molecular targets involved in feeding and metabolic regulation (Cascio et al., 2010; De Petrocellis et al., 2011) . Using a well-established prefeed satiation paradigm, we have recently shown that purified CBG stimulates multiple components of feeding behaviour, without detrimental motoric side-effects (Brierley et al., 2016a) . These previous data (reproduced here in Table 1 for reference) showed that purified CBG (120-240 mg/kg) increased the total food intake over a 2-h test. CBG-induced hyperphagia was predominantly due to increased appetitive behaviours, evidenced by increased frequency of feeding, rather than effects on meal sizes or durations.
Although testing the purified forms of pCBs is the rational first step in determining their pharmacological activities, in-vitro and in-vivo studies have shown that their botanical drug substance (BDS) form may have greater efficacy and/or potency (De Petrocellis et al., 2011; Hill et al., 2013) . Such BDSs (standardized extracts from chemotypes in which a particular pCB is dominant (De Meijer and Hammond, 2005) ) may exert differential effects to purified pCBs because of polypharmacology with the other low-abundance pCBs and/or terpenoids present, or by altered pharmacokinetics (Wagner and Ulrich-Merzenich, 2009 ). The present study was thus carried out to investigate the effects of a CBG-rich BDS (devoid of Δ 9 -THC) on feeding behaviours using an identical prefeed paradigm and dose range as that in our study of purified CBG.
Methods
The effects of CBG-BDS on feeding behaviour were investigated using our prefeed satiation paradigm as fully detailed in previous reports (Brierley et al., 2016a (Brierley et al., , 2016b 
Procedure
At the dark photoperiod onset, animals began a 2-h prefeed procedure, during which they had access to highly palatable wet-mash feed. Animals were habituated to this procedure until stable prefeed consumption levels were observed over 4 consecutive habituation days, determined by a nonsignificant effect of day (F 3, 63 = 0.56, NS).
On test days, animals completed the prefeed procedure and were immediately administered CBG-BDS or vehicle and returned to home cages for 1-h drug assimilation, during which food was unavailable. They were then placed into custom-designed feeder cages (270 × 405 mm) for the 2-h test, during which food consumption and locomotor activity were automatically recorded. Food intake monitors (TSE Systems, Bad Homburg, Germany) provided data on the time, duration and size of each feeding bout, which were combined into 'meals', defined as bouts consuming at least 0.5 g and separated by at least 900 s. Two levels of infrared activity monitors (Ugo Basile, Varese, Italy) were arrayed alongside the feeder cages, such that ambulatory locomotor activity was quantified by horizontal beam breaks in a plane 20 mm above the cage base and rearing behaviour by vertical breaks in a plane 120 mm high.
Drugs CBG-BDS was supplied by GW Research (Salisbury, UK), containing 72.2% w/w CBG, trace additional pCBs (CBGV: 0.4%; CBGA: 0.3%; CBC: 0.7%) and a non-pCB fraction including terpenoids and residual plant matter. Notably, this BDS contained no Δ 9 -THC. CBG-BDS or sesame seed oil vehicle was orally administered to 16 male Lister-hooded rats (Harlan, UK; 200-225 g on delivery) using a within-subjects design. Animals thus received doses of 0, 30, 60, 120 and 240 mg/kg (absolute mass of CBG-BDS) according to a pseudorandom, counterbalanced Latin square protocol, with at least 48 h washout period.
Data analysis
Data were analysed to provide measures of appetitive and consummatory behaviours using the parameters of latency to first meal and meal number (appetitive) and meal size and duration (consummatory). Ambulatory activity and rearing were quantified using horizontal and Table 1 Hourly food consumption and meal pattern analysis data Data presented as group mean SEM, analysed by one-way repeated-measures ANOVA and planned comparisons of all dose groups versus vehicle.
All groups n = 16.
ANOVA, analysis of variance; BDS, botanical drug substance; CBG, cannabigerol.
*P < 0.05. **P < 0.01. † Data for purified CBG has been previously published (Brierley et al., 2016a) and is reproduced here (http://creativecommons.org/licenses/by/4.0/), for comparison with CBG-BDS.
CBG-rich extract elicits hyperphagia Brierley et al. 281 vertical infrared beam breaks. Data were analysed by one-way repeated-measures analysis of variance, with significant overall effects followed by planned comparisons of all dose groups versus vehicle. Nonparametric data were analysed using Friedman's analysis of variance and Wilcoxon's signed rank comparisons. Results were considered significant if P values were less than 0.05.
Results
Consistent with previously reported effects of purified CBG, CBG-BDS significantly increased the total food intake during the test ( Fig. 1a ; F 2.2, 33.2 = 3.84, P < 0.05). The total intake was increased following the administration of CBG-BDS at 120 mg/kg (F 1, 15 = 8.23, P < 0.05) and 240 mg/kg (F 1, 15 = 11.10, P < 0.01), with animals consuming 1.53 0.39 and 1.36 0.39 g, respectively, compared with 0.56 0.26 g vehicle intakes.
Increased intake was predominantly driven by stimulation of appetitive feeding, evidenced by the dosedependently decreased latency to feeding onset (Figs. 1b and 2; χ 2 4 = 10.42, P < 0.05). All doses of CBG-BDS significantly decreased this latency, with maximal effects observed at 120 mg/kg (Z = − 2.81, P < 0.01), which advanced feeding onset by ∼ 40 min. The frequency of feeding was also increased, as shown by a significantly increased number of meals ( Fig. 1c; F 4, 60 = 3.76, P < 0.01). In contrast, although an increase in the cumulative size of the first two meals was observed (Table 1 ; F 2.1, 32.7 = 3.35, P < 0.05), the duration of meals, another measure of consummatory behaviour, was not significantly affected, including the cumulative duration of the first two meals (F 1.8, 26.4 = 2.58, NS) or of all meals combined (F 1.9, 27.7 = 3.10, NS). Corroborating the previously observed lack of detrimental motoric side-effects of purified CBG, CBG-BDS had no effect on either ambulatory activity (F 4, 60 = 1.89, NS) or rearing (F 4, 60 = 0.88, NS) over the 2-h test (Table 2) .
Discussion
CBG-BDS, at doses matched to our study of purified CBG, had similar effects on feeding patterns, despite the effective doses of CBG itself being ∼ 30% lower. Overall, animals administered CBG-BDS began feeding sooner, consumed more meals and consumed more within these meals. However, subtle differences were evident, indicating that although CBG-BDS has similar efficacy in this paradigm, it has apparently greater potency than purified CBG in stimulating feeding behaviours. The total intake over the test duration was maximally increased by ∼ 1 g following doses of 120 mg/kg, a three-fold increase versus vehicle. Purified CBG elicited a similar maximal increase of ∼ 1 g; however, this only represented a two-fold increase and was observed following the 240 mg/kg dose. Appetitive feeding behaviour, measured by decreased latency to feeding onset, was dose dependently stimulated by all doses of CBG-BDS, with a maximal reduction at 120 mg/kg of ∼ 40 min. In contrast, purified CBG only significantly advanced feeding onset at 240 mg/ kg, by ∼ 30 min. Both the number of meals and the Total food intake (a) and meal pattern microstructure parameters of latency to feeding onset (b) and number of meals consumed (c). Data presented as group mean SEM, analysed by one-way repeated-measures ANOVA (latency by Friedman's ANOVA) and planned comparisons of all dose groups versus vehicle. *P < 0.05, **P < 0.01. ANOVA, analysis of variance; BDS, botanical drug substance; CBG, cannabigerol.
cumulative size of the first two meals were approximately doubled by both 120 and 240 mg/kg CBG-BDS, in this case showing a consistent pattern of feeding stimulation to purified CBG. It is thus apparent that CBG-BDS is similarly efficaceous to purified CBG at stimulating feeding behaviours, but as the maximal effects were observed following doses of 120 mg/kg, it may be more potent, and shows a ceiling effect not observed following purified CBG.
Although determining the mechanism of action for this hyperphagia was beyond the scope of these studies, we have previously speculated on putative mechanisms on the basis of the published in-vitro affinities and activities of CBG (Brierley et al., 2016a) . In light of the apparent greater potency of CBG-BDS, such speculation can be extended on the basis of the differential affinities and activities reported in comparative in-vitro studies of the purified and BDS forms (De Petrocellis et al., 2011) . Although both have little affinity or activity at cannabinoid 1 or 2 receptors, they have similar efficacy as inhibitors of anandamide (AEA) reuptake, and may thus elicit hyperphagia by upregulation of orexigenic endocannabinoid tone. CBG-BDS has fourfold greater potency as an inhibitor of monoacylglycerol lipase (De Petrocellis et al., 2011) , the hydrolytic enzyme for 2-arachidonoylglycerol (2-AG). Given that 2-AG also elicits hyperphagia (Kirkham et al., 2002) , it is possible that the increased potency of CBG-BDS is due to concurrent elevation of 2-AG and AEA. The apparent ceiling effect of CBG-BDS at 120 mg/kg, not observed for purified CBG, also points to the potential involvment of another mechanism, involving the endocannabinoid-degrading enzyme N-acylethanolamine acid amide hydrolase. Although neither forms of CBG have appreciable activity as fatty acid amid hydrolase inhibitors, CBG-BDS alone is a potent inhibitor of N-acylethanolamine acid amide hydrolase, which would result in a selective inhibition of palmitoylethanolamine (PEA) hydrolysis over AEA. Given that PEA attenuates hyperphagia (Mattace Raso et al., 2014) , it is plausible that at CBG-BDS doses more than 120 mg/kg, PEA is elevated to physiologically relevant levels, attenuating CBG-induced hyperphagia mediated by other mechanisms. Although neither the minor pCBs nor terpenoids present in CBG-BDS have known appetitestimulating properties per se, they may improve the bioavailability of CBG and hence contribute toward the apparent greater potency of the BDS by pharmacokinetic effects (Wagner and Ulrich-Merzenich, 2009 ). Indeed, a recent study of the anticonvulsant effects of cannabidivarin-BDS showed that a pCB-free BDS was without intrinsic effect, but apparently slightly increased the efficacy of the purified pCB, supporting such a pharmacokinetic effect (Hill et al., 2013) . Although no direct pharmacokinetic comparison of purifed CBG and CBG-BDS has been published to date, it should be noted that purified forms of several major pCBs have shown differential brain concentrations dependent on the route of admininistration, with CBG reaching higher concentrations by the intraperitoneal route, in contrast to cannabidiol and CBDV for which the oral route was more effective (Deiana et al., 2012) . Further studies investigating the effects of intraperitoneal purified CBG and CBG-BDS on feeding behaviours may thus be warranted to determine which form, dose level and route of administration may have the greatest translational potential for cachexia.
Conclusion
Here we report for the first time that a CBG-rich BDS, devoid of Δ 9 -THC or other pCBs with known hyperphagic activity, stimulates appetite in presatiated rats. Graphical summary of group mean meal pattern microstructure parameters for meals 1 and 2. Boxes are positioned along the x-axis according to meal latencies, box widths are scaled to meal durations and meal sizes are given above. Where individual animals did not consume a second meal, minimum (size and duration) or maximum (latency) values were imputed. Asterisks indicate significantly decreased latencies compared with the vehicle, *P < 0.05, **P < 0.01. BDS, botanical drug substance; CBG, cannabigerol. CBG-BDS appears to have similar efficacy but greater potency than purified CBG, and warrants investigation as a potential novel treatment for cachexia.
